Maze Therapeutics Inc 2026年季度报告

OR MAZE THERAPEUTICS, INC. Delaware 82-2635018 (I.R.S. Employer Identification No.) 171 Oyster Point Blvd., Suite 300South San Francisco, California 94080(Address of principal executive offices, including zip code)(650) 850-5070(Registrant's telephone number, including area code)Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES☒NO☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). YES☒NO☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growthcompany. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the ExchangeAct. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financialaccounting standards provided pursuant to Section 13(a) of the Exchange Act.☐Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). YES☐NO☒As of August 5, 2026, the registrant had 55,549,168 shares of common stock outstanding. TABLE OF CONTENTS PageNumbers PART IFINANCIAL INFORMATION1Item 1.Financial Statements (Unaudited)1Condensed Balance Sheets1Condensed Statements of Operations and Comprehensive Loss2Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)3Condensed Statements of Cash Flows4Notes to Condensed Financial Statements5Item 2.Management's Discussion and Analysis of Financial Condition and Results of Operations18Item 3.Quantitative and Qualitative Disclosures About Market Risk28Item 4.Controls and Procedures28PART IIOTHER INFORMATION29Item 1.Legal Proceedings29Item 1A.Risk Factors29Item 2.Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities82Item 3.Defaults Upon Senior Securities82Item 4.Mine Safety Disclosures82Item 5.Other Information82Item 6.Exhibits83SIGNATURES84 Special note regarding forward-looking statements This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 21E of theSecurities Exchange Act of 1934, as amended, or the Exchange Act, Section 27A of the Securities Act of 1933, as amended, or theSecurities Act, and the Private Securities Litigation Reform Act of 1995. These statements appear throughout this Quarterly Reporton Form 10-Q and are statements regarding our intent, belief, or current expectations, primarily with respect to our business andrelated industry developments. In some cases, you can identify forward-looking statements by terms such as “believe,” “may,”“will,” “potentially,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “would,” “project,” “plan,” “expect” and similarexpressions that convey uncertainty of future events or outcomes, although not all forward-looking statements contain these words.These statements appear throughout this Quarterly Report on Form 10-Q and are statements regarding our intent, belief, or currentexpectations, primarily with respect to our business and related industry developments. These forward-looking statements aresubject to a number of risks, uncertainties and assumptions, including those described in “Risk Factors” and elsewhere in thisQuarterly Report on Form 10-Q. Moreover, we operate in a competitive and rapidly changing environment, and new risks emergefrom time to time. It is not possible to predict all risks, nor can we assess the impact of all factors on our business or the extent towhich any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events andcircumstances discussed in this Quarterly Report on Form 10-Q may not occur and actual results could differ materially andadversely from those anticipated or implied in the forward-looking statements. The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about: ii•the timing of our preclinical studies and clinical trials for our therapeutic candidates, including statements regarding theanticipated timing of initiation and completion of studies or trials